More good news ahead of the planned Phase 2 Study for Amplia’s lead drug candidate AMP945.
Amplia has today released new data in collaboration with the Garvan Institute of Medical Research showing AMP945 improves effectiveness of current standard of care treatments using human pancreatic cancer cells in an animal model.
Amplia has previously shown the addition of a pre‑treatment with AMP945 to a regimen of chemotherapy drugs gemcitabine/Abraxane® resulted in a 27% improvement in survival in the aggressive KPC mouse model of pancreatic cancer. The latest data shows AMP945 has now increased median survival by 33%.
Click here to read today’s ASX release.
